Imperative Care
Medtech company selling thrombectomy catheters, robotics and recovery tech for stroke, pulmonary embolism and peripheral vascular disease to hospitals and physicians.
Imperative Care develops and manufactures FDA-cleared access and aspiration thrombectomy catheters (Zoom stroke system, Symphony for DVT/PE, Prodigy for peripheral occlusion). It also develops Telos endovascular robotics and Kandu stroke-recovery technology. It sells to hospitals and neurointerventional and vascular physicians. The company is venture-backed and has raised about $600M in total, including a $260M Series D in 2021, a Series E in 2024 and a $100M convertible note in 2026. Third-party sources estimate 2025 revenue at about $162M (unverified), and headcount is roughly 420 as of mid-2026.
